|
WO2020077129A1
|
|
Human amylin analog polypeptides and methods of use
|
|
MX2019010651A
|
|
Apparatus and methods for administration of a nauseogenic compound from a drug delivery device.
|
|
CN110225762A
|
|
The method of the co-administration of continuous administration and drug including GLP-1 receptor stimulating agent
|
|
AU2017268161A1
|
|
Glucagon-receptor selective polypeptides and methods of use thereof
|
|
WO2017200944A1
|
|
Glucagon receptor/glp-1 receptor selective analog polypeptides and methods of use thereof
|
|
KR20180014814A
|
|
Implant placement and removal systems
|
|
US9889085B1
|
|
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
|
AU2014280920A1
|
|
Rapid establishment and/or termination of substantial steady-state drug delivery
|
|
AU2014268265A1
|
|
Highly concentrated drug particles, formulations, suspensions and uses thereof
|
|
CA2823721A1
|
|
Compositions, devices and methods of use thereof for the treatment of cancers
|
|
NZ731923A
|
|
Rapid establishment and/or termination of substantial steady-state drug delivery
|
|
NZ624569A
|
|
Rapid establishment and/or termination of substantial steady-state drug delivery
|
|
NZ592113A
|
|
Highly concentrated drug particles, formulations, suspensions and uses thereof
|
|
WO2009102467A2
|
|
Devices, formulations, and methods for delivery of multiple beneficial agents
|
|
AU2008244523A1
|
|
Suspension formulations of insulinotropic peptides and uses thereof
|
|
US2008226689A1
|
|
Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
|
|
NZ593017A
|
|
Piston assembly for positioning lumen in an osmotic delivery system having groove to retain elastomeric O-ring
|
|
KR20090003342A
|
|
Two-piece, internal-channel osmotic delivery system flow modulator
|
|
US2006246138A1
|
|
Polyoxaester suspending vehicles for use with implantable delivery systems
|
|
WO2006084139A2
|
|
An implantable interferon-containing device
|
